Comparative Pharmacology
Head-to-head clinical analysis: TIAGABINE HYDROCHLORIDE versus XCOPRI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIAGABINE HYDROCHLORIDE versus XCOPRI.
TIAGABINE HYDROCHLORIDE vs XCOPRI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tiagabine inhibits GABA reuptake into presynaptic neurons and glial cells by binding to the GAT-1 GABA transporter, thereby increasing synaptic GABA concentrations and enhancing inhibitory neurotransmission.
XCOPRI (cenobamate) is a tetrazole derivative anticonvulsant that reduces neuronal excitability through inhibition of voltage-gated sodium channels (persistent sodium current) and positive allosteric modulation of GABA-A receptors.
Initial: 4 mg orally once daily; titrate by 4-8 mg/day at weekly intervals. Maintenance: 32-56 mg/day divided 2-4 times daily. Maximum dose: 56 mg/day.
Oral, 100 mg once daily for 2 weeks, then increase to 200 mg once daily. Maximum dose 400 mg once daily.
None Documented
None Documented
Terminal half-life of 5–8 hours in healthy adults; prolonged to 12–16 hours in hepatic impairment. Reduces with enzyme-inducing co-medications.
50-70 hours, allowing once-daily dosing. Steady-state is reached in approximately 2 weeks.
Primarily hepatic metabolism via CYP3A4, with <2% excreted unchanged in urine. 63% of dose excreted in feces, 25% in urine as metabolites.
Primarily renal, with approximately 70% of the dose excreted as unchanged drug in urine and 30% as inactive metabolites. Fecal elimination accounts for <2%.
Category A/B
Category C
Anticonvulsant
Anticonvulsant